<div id="readability-page-1"><div><ul> <li>Last week, Intellia Therapeutics presented new long-term data at the European Society of Gene &amp; Cell Therapy Congress, highlighting approximately 90% sustained reductions in disease protein and no new safety issues for its gene-editing therapy NTLA-2001, while also announcing full enrollment in its Phase 3 HAELO study for hereditary angioedema.</li> <li>These clinical milestones reinforce Intellia's leading position in in vivo CRISPR therapeutics and have fueled increased optimism among analysts and investors about its upcoming regulatory milestones.</li> <li>We'll look at how the release of durable multi-year clinical data and rapid trial enrollment strengthens Intellia's investment narrative and commercial outlook.</li> </ul><p>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</p><h2>Intellia Therapeutics Investment Narrative Recap</h2><p> Investors in Intellia Therapeutics are essentially betting on the successful delivery and commercialization of first-in-class, in vivo CRISPR gene-editing therapies for rare genetic diseases. While the presentation of durable, multi-year results for NTLA-2001 and the completion of Phase 3 HAELO enrollment enhance confidence in near-term regulatory catalysts, the biggest risk remains the company's dependence on pivotal trial outcomes for its lead programs, as any clinical setback could severely delay future revenues and intensify reliance on external financing. The impact of these recent milestones directly strengthens the short-term case for value creation but does little to lower the inherent concentration risks tied to a narrow pipeline. </p> <p> Of the latest announcements, the most relevant is the release of three-year follow-up data showing sustained 90% reductions in pathogenic TTR protein and favorable clinical outcomes for ATTR amyloidosis patients treated with Intellia’s lead gene-editing candidate, nex-z. This mature dataset fortifies the clinical narrative underpinning ongoing regulatory submissions, and, when combined with accelerated trial enrollments, positions the company to hit key commercial and regulatory milestones over the next two years, which is likely supporting the current optimism in the stock. </p> <p> Yet, despite the excitement, investors should be aware that rapid progress in competitor gene-editing modalities could quickly make Intellia’s lead platform less differentiated if ... </p> <p>Read the full narrative on Intellia Therapeutics (it's free!)</p><p>Intellia Therapeutics' outlook anticipates $648.6 million in revenue and $104.2 million in earnings by 2028. This scenario assumes 130.7% annual revenue growth and a $584.4 million improvement in earnings from the current -$480.2 million.</p><p>Uncover how Intellia Therapeutics' forecasts yield a $34.08 fair value, a 39% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/926b118b-5d39-4424-95a8-7f467a4904b6/chart/community-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/926b118b-5d39-4424-95a8-7f467a4904b6/chart/community-fair-value"/><figcaption>NTLA Community Fair Values as at Oct 2025</figcaption></figure> <p> Seven fair value estimates from the Simply Wall St Community ranged from US$8.46 to US$34.08 per share. With the company’s unprofitability and heavy reliance on pivotal trial outcomes, you may want to compare these varying viewpoints to your own assessment. </p><p>Explore 7 other fair value estimates on Intellia Therapeutics - why the stock might be worth less than half the current price!</p><h2>Build Your Own Intellia Therapeutics Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Intellia Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.</li><li>Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li><li>The latest GPUs need a type of rare earth metal called Terbium and there are only 35 companies in the world exploring or producing it. Find the list for free.</li><li>AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

NTLA

<p>Intellia Therapeutics (NTLA) shares surged 22.8% following the presentation of long-term data showing 90% sustained reductions in disease protein and the completion of Phase 3 enrollment for its gene-editing therapy NTLA-2001. Analysts express increased optimism regarding upcoming regulatory milestones, although the company faces risks tied to pivotal trial outcomes. Revenue projections anticipate $648.6 million by 2028, with a fair value estimate of $34.08 per share, indicating a potential 39% upside from current prices. Investors are advised to consider varying fair value estimates and inherent risks before making decisions.</p>

Intellia Therapeutics (NTLA) Is Up 22.8% After Reporting Sustained Efficacy and Full Phase 3 Enrollment – Has the Bull Case Changed?